Atypical stromal cells of the lower female gynecologic tract were first described in the vagina by Norris and Taylor. 12 Since then, these cells have also been reported in the vulva and cervix, predominantly in the setting of fibroepithelial polyps (FEP). 5, 10, 13, 16 A case of bilateral fibroepithelial polyps of the labia minora containing atypical stromal cells was reported in 1992. 3 AbdulKarim and Cohen reported atypical stromal cells in the lower female genital tract (cervix, vagina, and vulva) as an incidental finding at autopsy. 1 While the occurrence of atypical stromal cells in endometrial polyps (EMPs) has been briefly alluded to, 7, 18 the first report of atypical stromal cells in a hyperplastic polyp was published in 1995. 8 We describe a series of 15 endometrial specimens (13 polyps, one curetting, and one biopsy) sent to the Armed Forces Institute of Pathology (AFIP) specifically because of the atypical (bizarre) stromal cells. 4, 11, 14 
MATERIALS AND METHODS
A systematic search of the AFIP database was conducted for cases containing the following key words: cervix, endometrium, floret type stromal cells, giant cells, stromal atypia, symplastic, uterus, vagina, and vulva. Cases from 1970 to the present were included in the search. Fifteen cases of endometrial specimens containing bizarre or atypical stromal cells were identified. The clinical histories and presentations were reviewed for all cases, and follow-up ranging from 1 month to 44 months (mean follow-up of 10 months) was obtained for 13 patients. No clinical follow-up was available for two cases. Hematoxylin and eosin-stained glass slides were examined for each case. Nine cases were evaluated immunohistochemically for expression of androgen receptor (BioGenex, San Ramon, CA, USA; 1:100), antimuscle actin (HUC1-1, Ventana, Tuscon, AZ, USA; prediluted), cytokeratin 8 
Clinical Features and Clinical Course
The patients ranged in age from 45 to 82 years (median 56 years, mean 59.7 years) at the time of presentation; none was pregnant (Table 1) . Of the 15 patients, 12 were postmenopausal; the remainder were either perimenopausal (one patient) or of unknown menopausal status (two patients, ages 45 and 54 years). Five (33.3%) of the patients were on hormone replacement therapy. Fourteen patients presented with dysfunctional uterine bleeding as the initial symptom. The remaining patient presented with pelvic pain and an enlarging uterus secondary to fibroids (case no. 9). One patient had a history of internal and external pelvic radiation secondary to a history of cervical carcinoma 16 years before presentation (case no. 2).
Two patients were initially treated with a total abdominal hysterectomy and bilateral salpingooophorectomy (TAH-BSO) for bleeding or enlarging fibroid uterus. The remaining 13 patients had an endometrial biopsy or curettage as the initial diagnostic procedure for the workup of dysfunctional uterine bleeding. Two of these 12 patients had TAH-BSO after a diagnosis of malignant mixed mesodermal tumor (MMMT) made on the initial endometrial biopsy. The previous biopsy was available for review on one of these cases diagnosed as MMMT, and it showed an EMP with atypical stromal cells; the hysterectomy specimen similarly did not display any evidence of MMMT (case no. 13) but had residual atypical stromal cells. The prior biopsy was not available for review in the second case; only the subsequent hysterectomy specimen was reviewed at AFIP, and it did not contain any evidence of MMMT (case no. 8) but did have residual atypical stromal cells.
Two patients who had an EMP with atypical stromal cells in an endometrial biopsy or endometrial curettage specimen had subsequent hysterectomy and bilateral salpingo-oophorectomy based on misinterpretation of the atypical stromal cells as malignant (MMMT, adenosarcoma, etc.). Only one of the two patients had any residual lesion in the follow-up hysterectomy specimen (case no. 8). The residual lesion consisted of what appeared to be the base of a polyp with scattered atypical stromal cells.
Ten patients had no further treatment (including the two whose lesions presented incidentally in TAH-BSO specimens). The remaining two patients had TAH-BSO for atypical (stromal) cells found in an initial curettage. One of these patients had persistent atypical stromal cells in the hysterectomy specimen (case no. 2), and the other patient had no residual lesion in the uterus (case no. 1). Follow-up was obtained for 13 women and ranged from 1 to 44 months. None of the patients has experienced a recurrence or metastasis to date.
The referring consultants' diagnoses on the material submitted to the AFIP for review included the following: adenosarcoma (one); dysplastic EMP (one); EMP, rule out neoplasia (one); EMP with clusters of atypical trophoblastic cells (one); EMP with stromal atypia, rule out sarcoma (one); EMP with atypical stromal cells, rule out endometrial stromal sarcoma (ESS) (three); EMP with atypical stromal cells (three); endometrial stromal atypia (without reference to a polyp) (three); and multinucleated stromal cells, possibly macrophages (one). The two diagnoses of MMMT were not made by the contributing pathologist but rather by another outside institution.
Histopathologic and Gross Features
All lesions were incidental findings in curettage or hysterectomy specimens performed for other reasons (e.g., dysfunctional uterine bleeding, fibroids), with the exception of the two cases misinterpreted as MMMT on biopsy. All atypical stromal cells were located within EMPs except for two cases (case nos. 4 and 10). Of the 13 cases involving EMP, four were subclassified as functional polyps, three were adenomyomatous, two were atrophic, two were hyperplastic, and two were mixed endometrial-endocervical polyps. The two cases that did not involve polyps were associated with proliferative phase (one) or disordered proliferative (one) endometrium. None of the cases was associated with endometrial carcinoma.
The atypical stromal cells consisted of moderately to severely atypical nuclei that were enlarged, hyperchromatic, and occasionally multinucleated (Fig. 1) . Although the cells appeared hyperchromatic at low magnification, on higher magnification it became evident that the hyperchromasia was not due to coarsened chromatin. Rather, the nuclei had a "smudged" appearance, much like the cells seen in atypical (symplastic) leiomyomas. Nucleoli were not a prominent feature but were present in scattered cases. Mitotic activity within the atypical stromal cells was not noted in any case. Many cases contained the giant cells within a loose fibrous background (Fig. 2) .
The distribution of the atypical cells within the endometrial samples was as follows: focal, seven cases; multifocal, five cases; and diffuse, three cases. In two of the seven cases in which the atypical cells were focally present, they were distributed in a band-like fashion just beneath the surface epithelium (Fig. 3) . In one case the cells were clustered at the base of the polyp, whereas they were located at the tip of the polyp in another case. Scattered inflammatory cells were present in some cases, but overall this was not a significant finding, except in case no. 10 in which numerous plasma cells were present and a diagnosis of chronic endometritis was made at AFIP.
The approximate size of the regions of involvement (in aggregate for multifocal lesions) ranged from 1 to 10 mm, with a mean and median size of 3.7 mm and 3.0 mm, respectively. The largest region of involvement was in case no. 1, which consisted of a diffuse distribution of atypical cells confined to a polyp.
Immunohistochemical Results
Nine cases were submitted for additional immunohistochemical staining. A positive result is defined as >5% of atypical stromal cells staining. All cases (100%) stained with vimentin, estrogen receptor, progesterone receptor, and androgen receptor (AR), similar to the adjacent control endometrial glands and stroma. Of the atypical stromal cells, 37.5% (three of eight cases) stained with CD10 and scattered cells stained with muscle markers (Table 2) .
DISCUSSION
In previous series that described atypical stromal cells primarily in the context of FEP, the patients ranged in age from 24 years 9 to 86 years. 4 In the series of lesions of the lower female genital tract (cervix, vulva, and va- gina) by Abdul-Karim and Cohen, 1 the patients ranged in age from 31 to 85 years. The 15 women in the current series ranged in age from 45 to 82 years, with a median and mean age of 56 years and 59.7 years, respectively; of the 13 women with known menopausal status, 12 were postmenopausal and one was perimenopausal. Only five of the 15 patients were on hormone replacement therapy at the time of diagnosis. In previous series the percentage of patients with atypical stromal cells in FEP who were pregnant at the time of diagnosis ranged from 5.5% 11 to as high as 48.5%. 14 In the current series of women (45 years or older), none of the patients was pregnant. Thus, in contrast to atypical stromal cells in other gynecologic sites, patients with endometrial lesions tend to be older, with postmenopausal bleeding as the presenting symptom. The hormonal status (i.e., pregnancy or exogenous hormone therapy) does not seem to be an etiologic factor.
The atypical stromal cells in our cases were generally scattered throughout the polyp, with rare cases containing cells clustered at the base (one patient), the tip (one patient), or distributed in a linear fashion beneath the surface epithelium (two patients; Fig. 3 ). The two cases not involving polyps contained atypical stromal cells scattered throughout the functionalis. Despite the hyperchromasia of these cells at low magnification, at higher magnification the chromatin had a smudgy rather than granular appearance (Fig. 1) . Of significance, mitotic figures were not identified within the atypical cell population.
The main differential diagnostic considerations include adenosarcoma, ESS, and MMMT/carcinosarcoma. EMPs are distinguished from adenosarcomas by the lack of stromal hypercellularity, periglandular stromal cuffing, formation of a cambium layer beneath the surface epithelium, polypoid or leaf-like projections into glandular lumina, increased stromal mitotic activity (>3 mitoses/10 high power fields), 20 or sarcomatous stromal overgrowth with homologous (i.e., ESS) or heterologous elements. 6 Discrimination from an ESS is relatively straightforward because ESSs have a distinct gross presentation as a mass lesion and an infiltrative histologic appearance. On gross inspection, endometrial stromal tumors are typically tan to yellow and even can be bright orange. 19 Microscopically, ESSs consist of a cellular proliferation of tightly packed spindled cells without a significant glandular component. Contrary to the clustered largecaliber vessels in polyps, ESSs contain a characteristic proliferation of small capillaries distributed evenly throughout the lesion. Areas of starburst hyalinization are occasionally noted. ESSs of the uterus extend into the myometrium, permeate throughout the uterus as wormlike masses, 17 and typically do not form pure polypoid lesions, although they may have a polypoid component. Atypical cells, particularly those with multinucleation or multilobulated nuclei, are extremely rare in ESSs.
A third diagnostic consideration is MMMT. By definition, an MMMT has both malignant glandular and stromal components. Similar to ESS, the sarcomatous component may contain either homologous or heterologous elements. None of our cases of EMP with atypical stromal cells was associated with a malignant epithelial component (adenocarcinoma). Although cellular atypia is a distinct feature of EMP with atypical stromal cells, increased mitotic activity of the atypical population was not present in any of our cases. If increased mitotic activity is noted among the atypical cells, then the possibility of an adenosarcoma (see above discussion) and an MMMT should be considered. The latter possibility is strengthened if a malignant glandular component is simultaneously present. In a curettage or biopsy sample, the possibility of MMMT is difficult to exclude given the fragmented nature of the specimen and the possibility of sampling error.
The etiology and precise nature of these atypical stromal cells encountered in the endometrium are unclear. In previous series some have postulated the atypical stromal cells to be of fibroblastic origin.
1,2 Based on our immunohistochemical findings in which the atypical stromal cells stain with characteristics of both endometrial stromal and smooth muscle differentiation, we propose that these atypical stromal cells represent a primitive cell population that arise from multipotent mesenchymal cells, which have the ability to differentiate toward either smooth muscle or endometrial stromal lineage. Origin of atypical cells from a multipotent mesenchymal cell population is supported by the existence of uterine tumors with features of both endometrial stromal and smooth muscle characteristics. 9, 15 Given their scattered presence in EMP, it is possible that the atypical cells are the result of a reactive or degenerative phenomenon, similar to the atypical cells present in symplastic leiomyomas. In view of the patients' age in our series, a degenerative process is more likely. The bizarre cells may have started to proliferate in response to an unknown stimulus with subsequent arrest of the proliferative process and a halt to further progression.
Regardless of their derivation, based on the clinical outcomes of the patients in our series, it appears that these changes are most likely benign despite their abnormal morphology. In most cases simple curettage or biopsy appears to be curative. Because of their rare nature and lack of significant long-term follow-up, however, continued clinical observation would be prudent. 
